This volume contains the proceedings of the William Harvey Conference held in London, 10-11 October, 1995. It covers the molecular biology and physiological functions of the cyclo-oxygenase enzymes, as well as the experimental and clinical aspects of the recently discovered inhibitors of the inducible cyclooxygenase.
Particular attention has been directed at the discussion of the selectivity of non-steroid anti-inflammatory drugs for cyclooxygenase-2 and their propensity to cause gastric and kidney damage.
Sir John Vane is the Director General, Regina Botting the Information Scientist, and Jack Botting Consultant at the William Harvey Research Institute, an independent charitable foundation carrying out research into cardiovascular disease inflammation and metabolic disorders within Queen Mary and Westfield College of the University of London, UK.
Sir John Vane was awarded the Nobel Prize in 1982 for his discoveries of the mechanism of action of aspirin and of the physiological role of prostacyclin and other prostanoids.
Particular attention has been directed at the discussion of the selectivity of non-steroid anti-inflammatory drugs for cyclooxygenase-2 and their propensity to cause gastric and kidney damage.
Sir John Vane is the Director General, Regina Botting the Information Scientist, and Jack Botting Consultant at the William Harvey Research Institute, an independent charitable foundation carrying out research into cardiovascular disease inflammation and metabolic disorders within Queen Mary and Westfield College of the University of London, UK.
Sir John Vane was awarded the Nobel Prize in 1982 for his discoveries of the mechanism of action of aspirin and of the physiological role of prostacyclin and other prostanoids.
